{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T05:57:36Z","timestamp":1789192656173,"version":"build-2803163510"},"reference-count":56,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T00:00:00Z","timestamp":1657497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Association pour la Recherche de Th\u00e9rapeutiques Innovantes en Canc\u00e9rologie"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>MiTF\/TFE translocation renal cell carcinoma (tRCC) is a rare and aggressive subtype of RCC representing the most prevalent RCC in the pediatric population (up to 40%) and making up 4% of all RCCs in adults. It is characterized by translocations involving either TFE3 (TFE3-tRCC), TFEB (TFEB-tRCC) or MITF, all members of the MIT family (microphthalmia-associated transcriptional factor). TFE3-tRCC was first recognized in the World Health Organization (WHO) classification of kidney cancers in 2004. In contrast to TFEB-tRCC, TFE3-tRCC is associated with many partners that can be detected by RNA or exome sequencing. Both diagnoses of TFE3 and TFEB-tRCC are performed on morphological and immunohistochemical features, but, to date, TFE break-apart fluorescent in situ hybridization (FISH) remains the gold standard for diagnosis. The clinical behavior of tRCC is heterogeneous and more aggressive in adults. Management of metastatic tRCC is challenging, especially in the younger population, and data are scarce. Efficacy of the standard of care-targeted therapies and immune checkpoint inhibitors remains low. Recent integrative exome and RNA sequencing analyses have provided a better understanding of the biological heterogeneity, which can contribute to a better therapeutic approach. We describe the clinico-pathological entities, the response to systemic therapy and the molecular features and techniques used to diagnose tRCC.<\/jats:p>","DOI":"10.3390\/ijms23147649","type":"journal-article","created":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T21:57:53Z","timestamp":1657576673000},"page":"7649","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["MiTF\/TFE Translocation Renal Cell Carcinomas: From Clinical Entities to Molecular Insights"],"prefix":"10.3390","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2943-0648","authenticated-orcid":false,"given":"Audrey","family":"Simonaggio","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP. Centre\u2014Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damien","family":"Ambrosetti","sequence":"additional","affiliation":[{"name":"Department of Pathology, CHU Nice, Universit\u00e9 C\u00f4te d\u2019Azur, F-06107 Nice, France"},{"name":"Institute for Research on Cancer and Aging of Nice (IRCAN), CNRS UMR 7284, INSERM U1081, University C\u00f4te d\u2019Azur, F-06107 Nice, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginie","family":"Verkarre","sequence":"additional","affiliation":[{"name":"Department of Pathology, H\u00f4pital Europ\u00e9en Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP. Centre\u2014Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"},{"name":"INSERM UMR-970, PARCC, Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1258-861X","authenticated-orcid":false,"given":"Marie","family":"Auvray","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP. Centre\u2014Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0893-285X","authenticated-orcid":false,"given":"St\u00e9phane","family":"Oudard","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP. Centre\u2014Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"},{"name":"INSERM UMR-970, PARCC, Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9410-1368","authenticated-orcid":false,"given":"Yann-Alexandre","family":"Vano","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, H\u00f4pital Europ\u00e9en Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP. Centre\u2014Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"},{"name":"INSERM UMR-970, PARCC, Universit\u00e9 Paris-Cit\u00e9, F-75015 Paris, France"},{"name":"Centre de Recherche des Cordeliers, INSERM, Universit\u00e9 Paris-Cit\u00e9, Sorbonne Universit\u00e9, F-75006 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,7,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21442","article-title":"Cancer Statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/ng.3146","article-title":"Spectrum of Diverse Genomic Alterations Define Non\u2013Clear Cell Renal Carcinoma Subtypes","volume":"47","author":"Durinck","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1002\/cncr.29368","article-title":"Characterization of Adolescent and Pediatric Renal Cell Carcinoma: A Report from the Children\u2019s Oncology Group Study AREN03B2","volume":"121","author":"Geller","year":"2015","journal-title":"Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.clgc.2016.05.013","article-title":"Clinicopathologic Features of Translocation Renal Cell Carcinoma","volume":"15","author":"Ellati","year":"2017","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.semdp.2015.02.003","article-title":"MiT Family Translocation Renal Cell Carcinoma","volume":"32","author":"Argani","year":"2015","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0165-4608(91)90184-V","article-title":"Cytogenetics of a Renal Cell Carcinoma in a 17-Month-Old Child. Evidence for Xp11.2 as a Recurring Breakpoint","volume":"57","author":"Tomlinson","year":"1991","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"110190","DOI":"10.1016\/j.celrep.2021.110190","article-title":"Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma","volume":"38","author":"Bakouny","year":"2022","journal-title":"Cell Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","article-title":"2004 WHO Classification of the Renal Tumors of the Adults","volume":"49","author":"Scarpelli","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/S0002-9440(10)64680-9","article-title":"A Distinctive Pediatric Renal Neoplasm Characterized by Epithelioid Morphology, Basement Membrane Production, Focal HMB45 Immunoreactivity, and t(6;11)(P21.1;Q12) Chromosome Translocation","volume":"158","author":"Argani","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/gcc.23007","article-title":"Translocation Carcinomas of the Kidney","volume":"61","author":"Argani","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours","volume":"70","author":"Moch","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_12","unstructured":"Argani, P., Martignoni, G., and Mehra, R. (2016). TFE3-Rearranged Renal Cell Carcinomas. WHO Classification of Tumours. Urinary and Male Genital Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cali\u00f2, A., Segala, D., Munari, E., Brunelli, M., and Martignoni, G. (2019). MiT Family Translocation Renal Cell Carcinoma: From the Early Descriptions to the Current Knowledge. Cancers, 11.","DOI":"10.3390\/cancers11081110"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Cheng, X., Gan, W., Zhang, G., Li, X., and Guo, H. (2016). Clinical Characteristics of XP11.2 Translocation\/TFE3 Gene Fusion Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Observational Studies. BMC Urol., 16.","DOI":"10.1186\/s12894-016-0154-6"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1200\/JCO.2005.04.4693","article-title":"Translocation Carcinomas of the Kidney After Chemotherapy in Childhood","volume":"24","author":"Argani","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"178.e3","DOI":"10.1016\/j.urology.2007.03.037","article-title":"Xp11 Translocation Renal Cell Carcinoma: Delayed but Massive and Lethal Metastases of a Chemotherapy-Associated Secondary Malignancy","volume":"70","author":"Drabick","year":"2007","journal-title":"Urology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/s41379-018-0051-5","article-title":"RNA Sequencing of Xp11 Translocation-Associated Cancers Reveals Novel Gene Fusions and Distinctive Clinicopathologic Correlations","volume":"31","author":"Wang","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1309\/LR5G1VMXPY3G0CUK","article-title":"Xp11.2 Translocation Renal Cell Carcinoma with Very Aggressive Course in Five Adults","volume":"128","author":"Meyer","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/modpathol.2013.208","article-title":"Clinical Heterogeneity of Xp11 Translocation Renal Cell Carcinoma: Impact of Fusion Subtype, Age, and Stage","volume":"27","author":"Ellis","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1038\/s41467-021-25618-z","article-title":"Integrated Exome and RNA Sequencing of TFE3-Translocation Renal Cell Carcinoma","volume":"12","author":"Sun","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/OP.21.00419","article-title":"Clinical Review on the Management of Metastatic Renal Cell Carcinoma","volume":"18","author":"Tran","year":"2022","journal-title":"JCO Oncol. Pract."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear Cell Renal Cell Carcinoma Ontogeny and Mechanisms of Lethality","volume":"17","author":"Jonasch","year":"2021","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/modpathol.2017.99","article-title":"Detection of 6 TFEB-Amplified Renal Cell Carcinomas and 25 Renal Cell Carcinomas with MITF Translocations: Systematic Morphologic Analysis of 85 Cases Evaluated by Clinical TFE3 and TFEB FISH Assays","volume":"31","author":"Skala","year":"2018","journal-title":"Mod. Pathol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/00000478-200306000-00005","article-title":"Aberrant Nuclear Immunoreactivity for TFE3 in Neoplasms with TFE3 Gene Fusions: A Sensitive and Specific Immunohistochemical Assay","volume":"27","author":"Argani","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1038\/modpathol.2009.58","article-title":"Cathepsin-K Immunoreactivity Distinguishes MiTF\/TFE Family Renal Translocation Carcinomas from Other Renal Carcinomas","volume":"22","author":"Martignoni","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/PAS.0b013e3182613d8f","article-title":"Molecular Confirmation of t(6;11)(P21;Q12) Renal Cell Carcinoma in Archival Paraffin-Embedded Material Using a Break-Apart TFEB FISH Assay Expands Its Clinicopathologic Spectrum","volume":"36","author":"Argani","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1002\/gcc.22985","article-title":"RBM10-TFE3 Fusions: A FISH-Concealed Anomaly in Adult Renal Cell Carcinomas Displaying a Variety of Morphological and Genomic Features: Comprehensive Study of Six Novel Cases","volume":"60","author":"Sibony","year":"2021","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1097\/PAS.0000000000001476","article-title":"Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer","volume":"44","author":"Williamson","year":"2020","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1038\/s41379-021-00803-z","article-title":"TRIM63 Is a Sensitive and Specific Biomarker for MiT Family Aberration-Associated Renal Cell Carcinoma","volume":"34","author":"Wang","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1158\/1078-0432.CCR-13-3036","article-title":"Next-Generation Sequencing of Translocation Renal Cell Carcinoma Reveals Novel RNA Splicing Partners and Frequent Mutations of Chromatin-Remodeling Genes","volume":"20","author":"Malouf","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/PAS.0000000000000631","article-title":"TFE3-Fusion Variant Analysis Defines Specific Clinicopathologic Associations Among Xp11 Translocation Cancers","volume":"40","author":"Argani","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2233","DOI":"10.1038\/sj.onc.1201394","article-title":"Fusion of Splicing Factor Genes PSF and NonO (P54nrb) to the TFE3 Gene in Papillary Renal Cell Carcinoma","volume":"15","author":"Clark","year":"1997","journal-title":"Oncogene"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1038\/sj.onc.1206686","article-title":"A Novel CLTC-TFE3 Gene Fusion in Pediatric Renal Adenocarcinoma with t(X;17)(P11.2;Q23)","volume":"22","author":"Argani","year":"2003","journal-title":"Oncogene"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/PAS.0000000000000835","article-title":"RBM10-TFE3 Renal Cell Carcinoma: A Potential Diagnostic Pitfall Due to Cryptic Intrachromosomal Xp11.2 Inversion Resulting in False-Negative TFE3 FISH","volume":"41","author":"Argani","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1097\/PAS.0000000000000927","article-title":"Melanotic Translocation Renal Cell Carcinoma with a Novel ARID1B-TFE3 Gene Fusion","volume":"41","author":"Antic","year":"2017","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s10024-005-0148-y","article-title":"Pediatric Renal Cell Carcinomas with Xp11.2 Rearrangements Are Immunoreactive for HMLH1 and HMSH2 Proteins","volume":"8","author":"Rakheja","year":"2005","journal-title":"Pediatr. Dev. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/his.13167","article-title":"Incidence, Clinicopathological Features and Fusion Transcript Landscape of Translocation Renal Cell Carcinomas","volume":"70","author":"Classe","year":"2017","journal-title":"Histopathology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s41379-018-0191-7","article-title":"NEAT1-TFE3 and KAT6A-TFE3 Renal Cell Carcinomas, New Members of MiT Family Translocation Renal Cell Carcinoma","volume":"32","author":"Pei","year":"2019","journal-title":"Mod. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/gcc.22261","article-title":"Identification of a Novel PARP14-TFE3 Gene Fusion from 10-Year-Old FFPE Tissue by RNA-Seq","volume":"54","author":"Huang","year":"2015","journal-title":"Genes. Chromosomes Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1097\/00000478-200212000-00003","article-title":"PRCC-TFE3 Renal Carcinomas: Morphologic, Immunohistochemical, Ultrastructural, and Molecular Analysis of an Entity Associated with the t(X;1)(P11.2;Q21)","volume":"26","author":"Argani","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/gcc.22801","article-title":"A Novel RBMX-TFE3 Gene Fusion in a Highly Aggressive Pediatric Renal Perivascular Epithelioid Cell Tumor","volume":"59","author":"Argani","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/gcc.22798","article-title":"Gene Fusion Analysis in Renal Cell Carcinoma by FusionPlex RNA-Sequencing and Correlations of Molecular Findings with Clinicopathological Features","volume":"59","author":"Tretiakova","year":"2020","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cancergencyto.2010.03.011","article-title":"A Novel Case of t(X;1)(P11.2;P34) in a Renal Cell Carcinoma with TFE3 Rearrangement and Favorable Outcome in a 57-Year-Old Patient","volume":"200","author":"Haudebourg","year":"2010","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1159\/000510241","article-title":"Characterization of Clinical Cases of Malignant PEComa via Comprehensive Genomic Profiling of DNA and RNA","volume":"98","author":"Akumalla","year":"2020","journal-title":"Oncology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1158\/1078-0432.CCR-12-3825","article-title":"Genomic Heterogeneity of Translocation Renal Cell Carcinoma","volume":"19","author":"Malouf","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3629","DOI":"10.1158\/1078-0432.CCR-19-3283","article-title":"Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression","volume":"26","author":"Marcon","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/annonc\/mdu445","article-title":"PD-L1 Expression in Nonclear-Cell Renal Cell Carcinoma","volume":"25","author":"Choueiri","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41379-020-00713-6","article-title":"TFEB Rearranged Renal Cell Carcinoma. A Clinicopathologic and Molecular Study of 13 Cases. Tumors Harboring MALAT1-TFEB, ACTB-TFEB, and the Novel NEAT1-TFEB Translocations Constantly Express PDL1","volume":"34","author":"Harada","year":"2021","journal-title":"Mod. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Research Network (2016). Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N. Engl. J. Med., 374, 135\u2013145.","DOI":"10.1056\/NEJMoa1505917"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5219","DOI":"10.1002\/cncr.25512","article-title":"Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Adult Metastatic Xp11.2 Translocation Renal Cell Carcinoma","volume":"116","author":"Choueiri","year":"2010","journal-title":"Cancer"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/annonc\/mdq029","article-title":"Targeted Agents in Metastatic Xp11 Translocation\/TFE3 Gene Fusion Renal Cell Carcinoma (RCC): A Report from the Juvenile RCC Network","volume":"21","author":"Malouf","year":"2010","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s40425-018-0482-z","article-title":"Immune Checkpoint Inhibitors in MITF Family Translocation Renal Cell Carcinomas and Genetic Correlates of Exceptional Responders","volume":"6","author":"Carlo","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.19.01882","article-title":"Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and\/or Sarcomatoid Features","volume":"38","author":"McGregor","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1200\/JCO.2021.39.6_suppl.274","article-title":"Efficacy of Cabozantinib in Advanced MiT Family Translocation Renal Cell Carcinomas (TRCC)","volume":"39","author":"Thouvenin","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic Correlates of Response to Immune Checkpoint Therapies in Clear Cell Renal Cell Carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/j.annonc.2021.09.014","article-title":"ESMO Clinical Practice Guideline Update on the Use of Immunotherapy in Early Stage and Advanced Renal Cell Carcinoma","volume":"32","author":"Powles","year":"2021","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7649\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:48:07Z","timestamp":1760140087000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/14\/7649"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,11]]},"references-count":56,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2022,7]]}},"alternative-id":["ijms23147649"],"URL":"https:\/\/doi.org\/10.3390\/ijms23147649","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,11]]}}}